Coronary Syndrome
📧 Sign up to get email alerts when something new happens for Coronary Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-12-22FDA Approved: EFFIENT — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA approved a supplemental application for EFFIENT (prasugrel hydrochloride) submitted by Cosette Pharmaceuticals, Inc.
-
FDA approval · 2020-12-11FDA Approved: AGGRASTAT — Supplemental Application (Medicure International Inc)
The FDA approved a supplemental application for AGGRASTAT (tirofiban) submitted by Medicure International Inc.
-
CLINICAL_TRIALS trial_result · 2020-11-24Clinical Trial Update: Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome [Phase 4]
A Phase 4 clinical trial evaluating the addition of evolocumab to moderate-intensity statin therapy for lowering LDL-C and assessing cardiov…
-
CLINICAL_TRIALS research · 2020-11-10Clinical Trial Update: Diagnostic Accuracy of Electrocardiogram for Acute Coronary Occlusion Resulting in Myocardial Infarction
A completed clinical trial assessing the diagnostic accuracy of electrocardiography for detecting acute coronary occlusion causing myocardia…
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: Inflammation Reduction by TREhalose AdminisTration [Phase 2]
Phase 2 clinical trial update evaluating trehalose administration for inflammation reduction in acute coronary syndrome.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-09-15FDA Approved: BRILINTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for Brilinta (ticagrelor) submitted by AstraZeneca Pharmaceuticals LP.
-
CLINICAL_TRIALS trial_result · 2020-09-09Clinical Trial Update: The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel [Phase 4]
Phase 4 trial update evaluating reloading prasugrel in patients who previously received a loading dose of clopidogrel in acute coronary synd…
-
CLINICAL_TRIALS trial_result · 2020-08-26Clinical Trial Update: Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study) [NA]
A terminated clinical trial investigating early psychological intervention to prevent PTSD after cardiovascular events; results posted in 20…
-
CLINICAL_TRIALS trial_result · 2020-08-25Clinical Trial Update: OPTImal Management of Antithrombotic Agents: OPTIMA-5 [Phase 4]
Phase 4 clinical trial update for OPTIMA-5 on managing antithrombotic agents in acute coronary syndrome.
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome [Phase 4]
Phase 4 trial comparing fixed-dose versus phenotype-based prasugrel dosing in Asians with acute coronary syndrome to match therapeutic windo…
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) [Phase 3]
Phase 3 trial update evaluating half-dose prasugrel and ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) completed.
-
CLINICAL_TRIALS trial_result · 2020-08-14Clinical Trial Update: APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF [Phase 4]
Phase 4 trial comparing apixaban versus phenprocoumon in patients with acute coronary syndrome and atrial fibrillation has completed.
-
CLINICAL_TRIALS trial_result · 2020-08-11Clinical Trial Update: Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome [Phase 4]
A Phase 4 clinical trial evaluating ivabradine's effect on inflammatory markers in patients with acute coronary syndromes has completed.
-
FDA approval · 2020-07-20FDA Approved: PRASUGREL — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for prasugrel submitted by Aurobindo Pharma Limited, granting approval of a generic prasugrel produc…
-
FDA approval · 2020-07-17FDA Approved: CLOPIDOGREL — Original Application (POLYGEN PHARMACEUTICALS INC.)
FDA approves Polygen Pharmaceuticals' original ANDA for a generic clopidogrel product.
-
FDA approval · 2020-07-15FDA Approved: HEPARIN SODIUM — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' generic heparin sodium (Original Application) as an injectable anticoagulant. It covers the same indi…
-
CLINICAL_TRIALS trial_result · 2020-07-10Clinical Trial Update: Colchicine in Percutaneous Coronary Intervention [Phase 4]
Phase 4 trial update evaluating colchicine in percutaneous coronary intervention for coronary artery disease and acute coronary syndrome; st…
-
CLINICAL_TRIALS trial_result · 2020-06-30Clinical Trial Update: Milrinone Versus Dobutamine in Critically Ill Patients [Phase 4]
Phase 4 trial comparing milrinone to dobutamine in critically ill patients with low cardiac output syndrome or cardiogenic shock has complet…
-
FDA approval · 2020-06-24FDA Approved: PRASUGREL — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application from Mylan Pharmaceuticals for prasugrel, enabling a generic prasugrel product. The indication c…
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial [Phase 4]
Phase 4 safety pilot trial evaluating hydroxychloroquine for prevention of cardiovascular events in patients with myocardial infarction or a…
-
CLINICAL_TRIALS trial_result · 2020-05-04Clinical Trial Update: Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel [Phase 2]
Phase 2 trial comparing crushed ticagrelor to eptifibatide bolus plus clopidogrel in acute coronary syndrome and unstable angina; study comp…
-
CLINICAL_TRIALS trial_result · 2020-04-30Clinical Trial Update: Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction [Phase 4]
Phase 4 trial evaluating individualized P2Y12 receptor antagonist therapy based on aggregometry versus fixed dosing after acute myocardial i…
-
CLINICAL_TRIALS trial_result · 2020-04-27Clinical Trial Update: The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery [Phase 3]
Phase 3 clinical trial assessing the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass graf…
-
CLINICAL_TRIALS trial_result · 2020-04-17Clinical Trial Update: MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction [Phase 3]
Phase 3 trial of magnesium-based bioresorbable scaffold for ST-elevation myocardial infarction has completed.
-
FDA approval · 2020-04-07FDA Approved: TICAGRELOR — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original application for ticagrelor from Novadoz Pharmaceuticals LLC. Ticagrelor is an antiplatelet medication used to redu…